| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Circulation. 2001;103:375.)
© 2001 American Heart Association, Inc.
Clinical Investigation and Reports |
Sex Differences in the Prognosis of Congestive Heart Failure
Results From the Cardiac Insufficiency Bisoprolol Study (CIBIS II)
From the Departments of Pharmacology (T.S., C.F.-B., P.J.) and Biostatistics (M.M.-K.), INSERM SC4, Paris VI University, Saint Antoine University Hospital, Rue Chaligny, Paris, France.
Correspondence to Dr Tabassome Simon, Pharmacology Department, Saint Antoine University, 27 Rue Chaligny, 75012 Paris, France. E-mail tabassome.simon{at}chusa.jussieu.fr
Background—Whether female sex is associated with a better prognosis in patients with congestive heart failure (CHF) remains uncertain. The Cardiac Insufficiency Bisoprolol Study (CIBIS) II showed that bisoprolol reduced all-cause mortality and morbidity rates in CHF patients treated with diuretics and ACE inhibitors. We examined whether survival was different in men (n=2132) and women (n=515) enrolled in CIBIS II.
Methods and Results—Women differed from men with regard to age, NYHA functional classification, primary cause of CHF, and risk factors such as left bundle-branch block. After adjustment for baseline differences, the probability of all-cause mortality was significantly reduced by 36% in women compared with that in men (hazard ratio 0.64, 95% CI 0.47 to 0.86, P=0.003). Women also had a 39% reduction in cardiovascular deaths (hazard ratio 0.64, 95% CI 0.45 to 0.91, P=0.01) and a 70% reduction in deaths from pump failure (hazard ratio 0.30, 95% CI 0.13 to 0.70, P=0.005) compared with men. Kaplan-Meier survival analysis revealed a significant reduction in all-cause mortality among women treated with bisoprolol compared with men (6% versus 12% P=0.01) but not among women treated with placebo (13% versus 18%, P=0.10). However, this sex/ß-blocker effect was not significant in multivariate analysis.
Conclusions—These results indicate that regardless of ß-blocker treatment and baseline clinical profile, female sex is a significant independent predictor of survival in patients with CHF.
Key Words: sex • women • heart failure • trials • antiarrhythmia agents
This article has been cited by other articles:
 |
|
 |
|
  C. L. Verheugt, C. S.P.M. Uiterwaal, E. T. van der Velde, F. J. Meijboom, P. G. Pieper, H. W. Vliegen, A. P.J. van Dijk, B. J. Bouma, D. E. Grobbee, and B. J.M. Mulder Gender and Outcome in Adult Congenital Heart Disease Circulation, July 1, 2008; 118(1): 26 - 32. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Barnes, M. Gott, S. Payne, C. Parker, D. Seamark, S. Gariballa, and N. Small Predicting mortality among a general practice-based sample of older people with heart failure Chronic Illness, March 1, 2008; 4(1): 5 - 12. [Abstract] [PDF]
|
|
|
|
 |
|
 P. Collins, G. Rosano, C. Casey, C. Daly, M. Gambacciani, P. Hadji, R. Kaaja, T. Mikkola, S. Palacios, R. Preston, et al. Management of cardiovascular risk in the peri-menopausal woman: a consensus statement of European cardiologists and gynaecologists Eur. Heart J., August 2, 2007; 28(16): 2028 - 2040. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. O'Meara, T. Clayton, M. B. McEntegart, J. J.V. McMurray, I. L. Pina, C. B. Granger, J. Ostergren, E. L. Michelson, S. D. Solomon, S. Pocock, et al. Sex Differences in Clinical Characteristics and Prognosis in a Broad Spectrum of Patients With Heart Failure: Results of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) Program Circulation, June 19, 2007; 115(24): 3111 - 3120. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. G. Frazier, K. P. Alexander, L. K. Newby, S. Anderson, E. Iverson, M. Packer, J. Cohn, S. Goldstein, and P. S. Douglas Associations of Gender and Etiology With Outcomes in Heart Failure With Systolic Dysfunction: A Pooled Analysis of 5 Randomized Control Trials J. Am. Coll. Cardiol., April 3, 2007; 49(13): 1450 - 1458. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 The ESHRE Capri Workshop Group Hormones and cardiovascular health in women Hum. Reprod. Update, September 1, 2006; 12(5): 483 - 497. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Stramba-Badiale, K. M. Fox, S. G. Priori, P. Collins, C. Daly, I. Graham, B. Jonsson, K. Schenck-Gustafsson, and M. Tendera Cardiovascular diseases in women: a statement from the policy conference of the European Society of Cardiology Eur. Heart J., April 2, 2006; 27(8): 994 - 1005. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Jochmann, K. Stangl, E. Garbe, G. Baumann, and V. Stangl Female-specific aspects in the pharmacotherapy of chronic cardiovascular diseases Eur. Heart J., August 2, 2005; 26(16): 1585 - 1595. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. D. Patten, I. Pourati, M. J. Aronovitz, J. Baur, F. Celestin, X. Chen, A. Michael, S. Haq, S. Nuedling, C. Grohe, et al. 17{beta}-Estradiol Reduces Cardiomyocyte Apoptosis In Vivo and In Vitro via Activation of Phospho-Inositide-3 Kinase/Akt Signaling Circ. Res., October 1, 2004; 95(7): 692 - 699. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Jessup and I. L. Pina Is it important to examine gender differences in the epidemiology and outcome of severe heart failure? J. Thorac. Cardiovasc. Surg., May 1, 2004; 127(5): 1247 - 1252. [Full Text] [PDF]
|
|
|
|
|
|
I. Gustafsson, B. Brendorp, M. Seibaek, H. Burchardt, P. Hildebrandt, L. Kober, C. Torp-Pedersen, and DIAMOND Study Group Influence of diabetes and diabetes-gender interaction on the risk of death in patients hospitalized with congestive heart failure J. Am. Coll. Cardiol., March 3, 2004; 43(5): 771 - 777. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Romo, A. C. K.-B. Amaral, and J.-L. Vincent Effect of Patient Sex on Intensive Care Unit Survival Arch Intern Med, January 12, 2004; 164(1): 61 - 65. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Gustafsson, C. Torp-Pedersen, H. Burchardt, P. Buch, M. Seibaek, E. Kjoller, I. Gustafsson, L. Kober, and for the DIAMOND Study group Female sex is associated with a better long-term survival in patients hospitalized with congestive heart failure Eur. Heart J., January 2, 2004; 25(2): 129 - 135. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. K. Ghali, H. J. Krause-Steinrauf, K. F. Adams Jr, S. S. Khan, Y. D. Rosenberg, C. W. Yancy Jr, J. B. Young, S. Goldman, M. A. Peberdy, and J. Lindenfeld Gender differences in advanced heart failure: insights from the BEST study J. Am. Coll. Cardiol., December 17, 2003; 42(12): 2128 - 2134. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Martinez-Selles, J. A.G. Robles, L. Prieto, M. D. Munoa, E. Frades, O. Diaz-Castro, and J. Almendral Systolic dysfunction is a predictor of long term mortality in men but not in women with heart failure Eur. Heart J., November 2, 2003; 24(22): 2046 - 2053. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 X.-M. Gao, A. Agrotis, D. J. Autelitano, E. Percy, E. A. Woodcock, G. L. Jennings, A. M. Dart, and X.-J. Du Sex Hormones and Cardiomyopathic Phenotype Induced by Cardiac {beta}2-Adrenergic Receptor Overexpression Endocrinology, September 1, 2003; 144(9): 4097 - 4105. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. H. Parker A Review of Cardiovascular Disease and Treatment Differences in Women Journal of Pharmacy Practice, June 1, 2003; 16(3): 157 - 163. [Abstract] [PDF]
|
|
|
|
|
|
T. Simon, M. Mary-Krause, C. Funck-Brentano, Ph. Lechat, P. Jaillon, and on behalf of CIBIS II investigators Bisoprolol dose-response relationship in patients with congestive heart failure: a subgroup analysis in the cardiac insufficiency bisoprolol study (CIBIS II) Eur. Heart J., March 2, 2003; 24(6): 552 - 559. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Jessup The less familiar face of heart failure J. Am. Coll. Cardiol., January 15, 2003; 41(2): 224 - 226. [Full Text] [PDF]
|
|
|
|
|
|
D. L. Crabbe, K. Dipla, S. Ambati, A. Zafeiridis, J. P. Gaughan, S. R. Houser, and K. B. Margulies Gender differences in post-infarction hypertrophy in end-stage failing hearts J. Am. Coll. Cardiol., January 15, 2003; 41(2): 300 - 306. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Muntwyler, G. Abetel, C. Gruner, and F. Follath One-year mortality among unselected outpatients with heart failure Eur. Heart J., December 1, 2002; 23(23): 1861 - 1866. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. K. Wenger Women, Heart Failure, and Heart Failure Therapies Circulation, April 2, 2002; 105(13): 1526 - 1528. [Full Text] [PDF]
|
|
|
|
 |
|
 S Orn and K Dickstein How do heart failure patients die? Eur. Heart J. Suppl., April 1, 2002; 4(suppl_D): D59 - D65. [Abstract] [PDF]
|
|
|
|
 |
|
 M. H. Farrell, J. M. Foody, and H. M. Krumholz {beta}-Blockers in Heart Failure: Clinical Applications JAMA, February 20, 2002; 287(7): 890 - 897. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. M Dart, X.-J. Du, and B. A Kingwell Gender, sex hormones and autonomic nervous control of the cardiovascular system Cardiovasc Res, February 15, 2002; 53(3): 678 - 687. [Full Text] [PDF]
|
|
|
|
|
|
J. K. Ghali, T. Simon, M. Mary-Krause, C. Funck-Brentano, and P. Jaillon Sex Differences in the Prognosis of Congestive Heart Failure Response Circulation, October 9, 2001; 104 (15): e81 - e81. [Full Text] [PDF]
|
|
|
|
|
|
M.-D. Drici Influence of gender on drug-acquired long QT syndrome Eur. Heart J. Suppl., September 1, 2001; 3(suppl_K): K41 - K47. [Abstract] [PDF]
|
|
|
|
|
|
P. Lechat, J.-S. Hulot, S. Escolano, A. Mallet, A. Leizorovicz, M. Werhlen-Grandjean, G. Pochmalicki, and H. Dargie Heart Rate and Cardiac Rhythm Relationships With Bisoprolol Benefit in Chronic Heart Failure in CIBIS II Trial Circulation, March 13, 2001; 103(10): 1428 - 1433. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. K. Ghali, I. L. Pina, S. S. Gottlieb, P. C. Deedwania, J. C. Wikstrand, and on Behalf of the MERIT-HF Study Group Metoprolol CR/XL in Female Patients With Heart Failure: Analysis of the Experience in Metoprolol Extended-Release Randomized Intervention Trial in Heart Failure (MERIT-HF) Circulation, April 2, 2002; 105(13): 1585 - 1591. [Abstract] [Full Text] [PDF]
|
|